pink-ribbon-14306811601dc-222x300-5897610State legislators have taken their mania for insurance mandates to a new extreme: They’ve passed a bill that arguably accomplishes nothing other than covering unnecessary mammograms.

Unless vetoed by Governor Andrew Cuomo, this mandate would not only waste millions, but possibly do more harm than good for the women it’s supposed to help.

The bill in question, sponsored by Senator Joseph Griffo of Rome and Assemblywoman Rebecca Seawright of Manhattan, adds “breast tomosynthesis,” a high-tech form of mammography, to the long list of procedures that state-regulated health plans must pay for.

Approved by the Food and Drug Administration in 2011, the technique generates a 3-D X-ray image of the breast, and shows promise of more accurately identifying signs of cancer, especially in the roughly half of women who have dense breast tissue.

However, the U.S. Preventive Services Task Force and other experts say there is not yet enough clinical evidence to show that the technique improves health outcomes in women of average risk, as has been proven with traditional mammograms.

In the face of this scientific uncertainty, Governor Cuomo announced in February that regulators at the Department of Financial Services were ordering health plans to cover tomosynthesis “when medically necessary.” The order seemed largely symbolic, since the state Health Plan Association said its members already covered tomosynthesis when medically necessary.

But the DFS rule left plans with sensible discretion to limit coverage – such as covering the procedure only for women with dense breast tissue or a family history of breast cancer, or simply requiring a doctor’s recommendation.

Had the Legislature simply codified the same rule as law, that would be bad enough. Writing medical guidelines into statute is a dangerous business, especially when the science remains unsettled.

But the Griffo-Seawright mandate bill goes well beyond the DFS rule. It includes no mention of medical necessity, family history, dense tissue, or a doctor’s recommendation. Instead, it expands the state’s existing mammography mandate to include tomosynthesis, effectively adding it as a routine procedure for all women.

Since the DFS has previously mandated coverage of medically necessary tomosynthesis screens, the only practical impact of Griffo-Seawright is to require coverage, by law, for unnecessary ones.

Already, the state’s existing screening law, written years ago, goes beyond the current guidelines of expert organizations. For women of average risk, it requires coverage of a baseline mammogram as young as 35, then yearly screens starting at 40 with no upper age limit.

The Preventive Services Task Force, by contrast, recommends every-other-year mammograms from 50 to 74 for average women, and starting at age 40 for women at high risk.

The task force based its guidelines not on cost, but on the potential harm of excessive screening – including the anxiety and unnecessary biopsies and treatments that result from false alarms.

But of course mammograms of all kinds cost money, and requiring payment for unnecessary procedures will only add to the high cost of healthcare in New York State.

Despite these concerns, the Assembly approved Griffo-Seawright unanimously on March 30, and the Senate did the same on Thursday.

As Trudy Lieberman of Health News Review wrote earlier this year, regarding the DFS order: “Breast cancer is good politics, and when votes are at stake, inconvenient or nuanced science gets overlooked.”

About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

How a Medicaid Program To Improve Nursing Home Care Ended Up Paying for Union Benefits

New York State's budget-making process sometimes works like a closed loop, as interest groups on the receiving end of state spending reinvest a portion of their proceeds to lobby Albany for still more money. Read More

Hochul’s ‘Straight Talk’ on Medicaid Isn’t Straight Enough

Arguably the biggest Medicaid news in Governor Hochul's budget presentation was about the current fiscal year, not the next one: The state-run health plan is running substantially over budget. Read More

Despite Lingering Shortages, New York’s Health-Care Workforce Is Bigger Than Ever

The state's health-care workforce is recovering unevenly from the pandemic, with persistently lower employment levels in some areas and robust growth in others. This mixed pattern c Read More

The Wacky Math of New York’s Essential Plan

Thanks to an absurdly wasteful federal law, New York's Essential Plan is expected to continue running billion-dollar surpluses even as state officials more than double its spending over the next several years. Read More

In a Tight Budget Year, New York’s Hospital Lobby Shoots for the Moon

As Governor Hochul calls for spending restraint next year, influential hospital lobbyists are pushing what could be the costliest budget request ever floated in Albany. In a , the G Read More

Putting the Mission in Hochul’s Health Commission

Last week Governor Hochul answered one big question about her Commission on the Future of Health Care – the names of its members – but left a fundamental mystery unresolved:  W Read More

Medicaid Drug ‘Carve-Out’ Led to Double Payments

The state's Medicaid program has effectively been double-paying for prescription drugs for the past six months due to a glitch with the roll-out of its pharmacy "carve-out." Since A Read More

DFS Pulls Back Draft Regulations That Would Have Added a Fee for Prescriptions

A package of proposed regulations that included a $10.18 fee for filling most drug prescriptions was withdrawn Tuesday by the Department of Financial Services in the face of broad opposition. Read More